Targeting HER2-positive breast cancer: advances and future directions
SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
Network pharmacology: curing causal mechanisms instead of treating symptoms
For complex diseases, most drugs are highly ineffective, and the success rate of drug
discovery is in constant decline. While low quality, reproducibility issues, and translational …
discovery is in constant decline. While low quality, reproducibility issues, and translational …
[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Rational combinations of targeted cancer therapies: background, advances and challenges
Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …
HER2-targeted therapies—a role beyond breast cancer
DY Oh, YJ Bang - Nature reviews Clinical oncology, 2020 - nature.com
HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Background Systemic therapies for metastatic biliary tract cancers are few, and patients
have a median overall survival of less than 1 year. MyPathway evaluates the activity of US …
have a median overall survival of less than 1 year. MyPathway evaluates the activity of US …
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …